CN109641856A - 缬沙坦二钠盐的晶型 - Google Patents

缬沙坦二钠盐的晶型 Download PDF

Info

Publication number
CN109641856A
CN109641856A CN201680088890.3A CN201680088890A CN109641856A CN 109641856 A CN109641856 A CN 109641856A CN 201680088890 A CN201680088890 A CN 201680088890A CN 109641856 A CN109641856 A CN 109641856A
Authority
CN
China
Prior art keywords
crystal form
disodium salt
valsartan disodium
salt crystal
valsartan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201680088890.3A
Other languages
English (en)
Other versions
CN109641856B (zh
Inventor
刘飞
吴刚
姜伟明
林成刚
蔡璇
林萍
陆玉玲
刘立湘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Noratech Pharmaceuticals Co ltd
Original Assignee
Noratech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noratech Pharmaceuticals Inc filed Critical Noratech Pharmaceuticals Inc
Publication of CN109641856A publication Critical patent/CN109641856A/zh
Application granted granted Critical
Publication of CN109641856B publication Critical patent/CN109641856B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

提供一类缬沙坦二钠盐的晶型A、B、D、E、F、G和H及其制备方法。

Description

PCT国内申请，说明书已公开。

Claims (26)

  1. PCT国内申请，权利要求书已公开。
CN201680088890.3A 2016-09-02 2016-09-02 缬沙坦二钠盐的晶型 Active CN109641856B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/097926 WO2018040065A1 (zh) 2016-09-02 2016-09-02 缬沙坦二钠盐的晶型

Publications (2)

Publication Number Publication Date
CN109641856A true CN109641856A (zh) 2019-04-16
CN109641856B CN109641856B (zh) 2022-09-30

Family

ID=61299687

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680088890.3A Active CN109641856B (zh) 2016-09-02 2016-09-02 缬沙坦二钠盐的晶型

Country Status (4)

Country Link
US (1) US10745363B2 (zh)
EP (1) EP3508479A4 (zh)
CN (1) CN109641856B (zh)
WO (1) WO2018040065A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230057675A1 (en) * 2019-12-02 2023-02-23 Harman Finochem Limited A process for the preparation of highly pure valsartan

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0443983A1 (de) * 1990-02-19 1991-08-28 Ciba-Geigy Ag Acylverbindungen
CN1443176A (zh) * 2000-07-19 2003-09-17 诺瓦提斯公司 缬沙坦的盐
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds
CN102596899A (zh) * 2009-10-27 2012-07-18 诺瓦提斯公司 制备有机化合物的方法
CN102702119A (zh) * 2005-11-09 2012-10-03 诺瓦提斯公司 血管紧张素受体拮抗剂和nep抑制剂的药物组合产品
WO2016074651A1 (en) * 2014-11-14 2016-05-19 Zentiva, K.S. A method for the preparation, isolation and purification of pharmaceutically applicable forms of ahu-377
WO2016125123A1 (en) * 2015-02-06 2016-08-11 Mylan Laboratories Limited Amorphous trisodium sacubitril valsartan and a process for the preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN201813039U (zh) 2010-10-18 2011-04-27 重庆长安汽车股份有限公司 一种汽车线束连接器卡扣
EP3828175A1 (en) * 2015-06-12 2021-06-02 Teva Pharmaceuticals International GmbH Solid state forms of trisodium valsartan: sacubitril
EP3117823A1 (en) * 2015-07-17 2017-01-18 Quimica Sintetica, S.A. Amorphous solid dispersion comprising an angiotensin receptor blocker and a neutral endopeptidase inhibitor
WO2019020706A1 (en) * 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0443983A1 (de) * 1990-02-19 1991-08-28 Ciba-Geigy Ag Acylverbindungen
CN1443176A (zh) * 2000-07-19 2003-09-17 诺瓦提斯公司 缬沙坦的盐
CN102702119A (zh) * 2005-11-09 2012-10-03 诺瓦提斯公司 血管紧张素受体拮抗剂和nep抑制剂的药物组合产品
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds
CN102596899A (zh) * 2009-10-27 2012-07-18 诺瓦提斯公司 制备有机化合物的方法
WO2016074651A1 (en) * 2014-11-14 2016-05-19 Zentiva, K.S. A method for the preparation, isolation and purification of pharmaceutically applicable forms of ahu-377
WO2016125123A1 (en) * 2015-02-06 2016-08-11 Mylan Laboratories Limited Amorphous trisodium sacubitril valsartan and a process for the preparation thereof

Also Published As

Publication number Publication date
US10745363B2 (en) 2020-08-18
EP3508479A1 (en) 2019-07-10
EP3508479A4 (en) 2020-02-19
CN109641856B (zh) 2022-09-30
WO2018040065A1 (zh) 2018-03-08
US20190194149A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
CN113527203B (zh) 乐伐替尼甲磺酸盐的晶型及其制备方法和用途
CA2746652C (en) Crystalline forms of genistein
CN106420743A (zh) C‑met调节剂药物组合物
CN105085517B (zh) 一种结晶型帕博西尼游离碱水合物及其制备方法
CN105732575A (zh) 一种治疗***癌的新型抗雄激素类药物的新晶型及其制备方法
JP6752822B2 (ja) キナゾリンクロチル化合物二マレイン酸塩結晶、ならびに、その調製方法および使用
CN109641856A (zh) 缬沙坦二钠盐的晶型
CN104478815A (zh) 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-***-3-基硫基)乙酸的多种盐、它们的晶型及其制备方法
US7863325B2 (en) Crystalline genistein sodium salt dihydrate
MXPA05009129A (es) Procedimiento para la produccion de sal acida de adicion de compuesto acido poliacido.
CN115385893A (zh) 与吡啶酰基哌啶5-ht1f激动剂相关的组合物和方法
CN105085476B (zh) 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺二盐酸盐的晶型及其制备方法
EP3846906A1 (en) Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor
TWI648267B (zh) 纈沙坦二鈉鹽新晶型
CN109232582A (zh) 拉洛替尼硫酸氢盐晶型及其制备和应用
CA3122189A1 (en) Crystalline forms of 1-[(3r,4s)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]pyrazole-4-carboxamide
WO2022171117A1 (zh) 含氮稠杂环化合物的盐、晶型及其制备方法、药物组合物和用途
CN109661386A (zh) 沙库比曲钠盐新晶型
JP2023545165A (ja) 多置換ベンゼン環化合物マレイン酸塩の結晶形、その調製方法及びその用途
CN103003253A (zh) 2-{2-[[(4-甲氧基-2,6-二甲基苯基)磺酰基]-(甲基)氨基]乙氧基}-n-甲基-n-[3-(4-甲基哌嗪-1-基)环己基]乙酰胺的酸加成盐及其作为缓激肽b1受体拮抗剂的用途
CN108699007A (zh) 氟班色林的新晶型及其制备方法及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20191224

Address after: 6 / F, building F6, No.9, Weidi Road, Jiangsu life science and Technology Innovation Park, Qixia District, Nanjing City, Jiangsu Province

Applicant after: NANJING NORATECH PHARMACEUTICALS Co.,Ltd.

Address before: Taipei City, Taiwan, China

Applicant before: NORATECH PHARMACEUTICALS, Inc.

GR01 Patent grant
GR01 Patent grant